FY 24-25 performance

Share of revenue from India market
0 %
Compounded annual revenue growth over 3 years
0 %
Return on Capital Employed
%
FY25 Revenue from operations
0 Cr
Earnings per share
Compound annual total return to shareholders over the last 5 fiscal years
0 %
Total FY24 revenues, an increase of 2% in local currency
$ 0 B
FY24 adjusted EPS, a 2% increase over FY23 adjusted EPS; $11.44 FY24 GAAP EPS, a 6% increase.
$ 0
Compound annual total return to shareholders over the last 5 fiscal years
$ 0 B
FY24 cash returned to shareholders
$ 0 B
FY24 adjusted EPS, a 2% increase over FY23 adjusted EPS; $11.44 FY24 GAAP EPS, a 6% increase.
$ 0

Driving Sustainable Growth and Innovation

Emcure is committed to creating long-term value through innovation, operational excellence, and a steadfast focus on delivering impactful healthcare solutions. Guided by a strong foundation of integrity and performance, we strive to achieve sustainable growth while addressing critical medical needs globally.

Annual Report of FY 2023-24

Gennova Biopharmaceuticals Limited Financials March 2024

Zuventus Healthcare Limited Financials March 2024

Emcure UK INR Converted Financials FY 2024

Marcan INR Converted Financials FY 2024

Tillomed UK INR Converted Financials FY 2024

Gennova Biopharmaceuticals Ltd. – Financial Statement 2023

Gennova Biopharmaceuticals Ltd. – Financial Statement 2022

Gennova Biopharmaceuticals Ltd. – Financial Statement 2021

Zuventus Healthcare Ltd – Financial Statement 2023

Zuventus Healthcare Ltd – Financial Statement 2022

Zuventus Healthcare Ltd – Financial Statement 2021

Emcure UK INR Converted Financial

Tillomed UK INR Converted Financial

Marcan INR Converted Financial

Gennova Biopharmaceuticals Limited Financials March 2024

Zuventus Healthcare Limited Financials March 2024

Emcure UK INR Converted Financials FY 2024

Marcan INR Converted Financials FY 2024

Tillomed UK INR Converted Financials FY 2024

Gennova Biopharmaceuticals Ltd. – Financial Statement 2023

Gennova Biopharmaceuticals Ltd. – Financial Statement 2022

Gennova Biopharmaceuticals Ltd. – Financial Statement 2021

Zuventus Healthcare Ltd – Financial Statement 2023

Zuventus Healthcare Ltd – Financial Statement 2022

Proceedings of Postal Ballot – December 2024

Voting Results of Postal Ballot along with Scrutinizer’s Report – December 2024​

Notice of Postal Ballot – 7th November 2024

Notice of 43rd Annual General Meeting – 5th June 2024

Newspaper Publication of Unaudited Financial Results – Q4 FY25

Newspaper Publication of Unaudited Financial Results – Q3 FY25

Newspaper Publication of Postal Ballot Notice – 7th November 2024

Newspaper Publication of Unaudited Financial Results – Q2 FY25

Newspaper Publication of Unaudited Financial Results – Q1 FY25

Credit Ratings

Credit Ratings

Rating Agency
Instrument Type
Rating

CRISIL Ratings Limited

Long Term Rating

CRISIL AA- / Stable (upgraded from CRISIL A+ / Stable)

Short Term Rating

CRISIL A1+ (upgraded from CRISIL A1)

CARE Ratings Limited

Long-term bank facilities

CARE AA; Stable (upgraded from CARE AA-; Stable)

Long-term / Short-term bank facilities

CARE AA; Stable / CARE A1+ (Long-term rating upgraded from CARE AA-; Stable and Short-term rating reaffirmed)

Short-term bank facilities

CARE A1+ (Reaffirmed)

Annual Secretarial Compliance Report FY 2024-25

Investor Presentation 25-26

Quarterly Results

Q1

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q2

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q3

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q4

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q1

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q2

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q3

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q4

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Details of Business

Brief profile of Board of Directors

Committees of the Board

Emcure – Memorandum and Articles of Association

Code of Conduct for Directors and Senior Management

Vigil Mechanism Policy

CSR Policy and Composition of CSR Committee

Nomination and Remuneration Policy

Archival Policy

Dividend Distribution Policy

Policy for Preservation of Documents

Policy for Determining Material Subsidiaries

Terms and Conditions of Appointment of Independent Director

Familiarisation Program for Independent Directors

Details of Familiarization Programme Imparted to Independent Directors

Policy for Determining Materiality of Events and Information for Disclosures

Related Party Transactions Policy

Code for Prohibition of Insider Trading – Till June 09, 2025

Code for Prohibition of Insider Trading – w.e.f. June 10, 2025

Emcure – Employee Stock Option Scheme 2013

Shareholding Pattern

Disclosures under Regulation 30

Disclosures under Regulation 32

Corporate Governance Filings

Board Meeting Intimation

Financial Results

Financial Results published in Newspaper

Notices to Shareholders

Annual Report

Annual Returns

Annual Secretarial Compliance Report

Credit Ratings

Financial Statement of Subsidiary Companies

Schedule of analysts or institutional investors meet

Presentations made by the Company to analysts or institutional investors

Audio or video recordings and transcripts of post earnings/quarterly calls

Intimation under Regulation 30(5) – Details of KMPs

Email address for grievance redressal and other relevant details

Loading...

Loading...

Loading...

SEBI
In case the Complaint/grievance stands unresolved/not resolved up to the satisfaction of Investor(s), may lodge a complaint with:

SEBI SCORES Portal: https://scores.gov.in/scores/Welcome.html

Online Dispute Resolution (Smart ODR) Platform: https://smartodr.in/login